Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/valsartan (Entresto) continued to deliver reductions in the heart failure biomarker N-terminal pro–B-type natriuretic peptide (NT-proBNP), an established biomarker for heart failure severity and prognosis.[1] The data was presented as a late-breaker at the American College of Cardiology (ACC) 2019 Annual Scientific Session in March.
News | Heart Failure | March 27, 2019
March 27, 2019 —New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/...
Stopping DAPT After One Month Improved Outcomes in Stent Patients
News | Antiplatelet and Anticoagulation Therapies | March 25, 2019
March 25, 2019 — Patients who stopped taking aspirin one month after receiving a stent in the heart’s arteries but...
Bempedoic Acid Combination Tablet Significantly Lowers LDL-Cholesterol

Image courtesy of Esperion

News | Pharmaceuticals | March 25, 2019
March 25, 2019 — Phase 3 results from Study 2, also known as CLEAR WISDOM, of bempedoic acid were recently presented at...
Apixaban Effective in Specific Cohort of Non-Valvular Atrial Fibrillation Patients
News | Antiplatelet and Anticoagulation Therapies | March 19, 2019
March 19, 2019 — The Bristol-Myers Squibb-Pfizer Alliance announced results from the Phase 4 AUGUSTUS trial evaluating...

The opening late-breaking trial at ACC 2019 is the Apple Heart Study, a large-scale, app-based study to identify atrial fibrillation using a smartwatch. Earlier, smaller trials showed this approach might be used in a population health application to proactively identify AFib patients earlier.

Feature | ACC | March 19, 2019
The American College of Cardiology (ACC) released a list of the latest practice-changing presentations at the ACC.19...
ACC/AHA Update Guidance for Preventing Heart Disease; Stroke
Feature | Cardiac Diagnostics | March 18, 2019
March 18, 2019 — The choices we make every day can have a lasting effect on our heart and vascular health. Adopting a...
Researchers Develop Reversible, Drug-Free Antiplatelet Therapy
News | Antiplatelet and Anticoagulation Therapies | February 19, 2019
February 19, 2019 — A new reversible, drug-free antiplatelet therapy could reduce the risk of blood clots and...
Two of the top news items from January included news atrial fibrillation guidelines that now recommend new anticoagulants (NOACs) over warfarin, and the FDA warning hospitals about the increased mortality found in one study involving pacitaxel-eluting stents and balloon devices for the peripheral arteries.

Two of the top news items from January included news atrial fibrillation guidelines that now recommend new anticoagulants (NOACs) over warfarin, and the FDA warning hospitals about the increased mortality found in one study involving pacitaxel-eluting stents and balloon devices for the peripheral arteries. 

Feature | February 01, 2019 | Dave Fornell, Editor
February 1, 2019 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC)...
Research Sheds Light on Blood Pressure Drug Function
News | Hypertension | January 31, 2019
January 31, 2019 — Researchers have mapped the active-state structure of the angiotensin II type 1 receptor, the target...
Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.

Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.

 

Feature | Atrial Fibrillation | January 30, 2019
January 30, 2019 — Updated atrial fibrillation (AFib) treatment guidelines released this week now recommend new oral...
The startup company Genetesis introduced a new cardiac imaging modalityit calls magnetocardiography. The scanner creates images from the biomagnetic activity of the heart, using the polarization and depolarization of the heart during the cardiac cycle. This was at AHA.18, AHA 2018 - the American Heart Association annual meeting

The startup company Genetesis introduced a new cardiac imaging modality it calls magnetocardiography. The scanner creates images from the biomagnetic activity of the heart, using the polarization and depolarization of the heart during the cardiac cycle.

Feature | AHA | January 14, 2019 | Dave Fornell, Editor
Here are a few of the takeaways from the clinical studies presented and new technology shown on the exhibit floor at...
Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc. is conducting a voluntary recall of 80 lots of Amlodipine Valsartan...
The 2018 Most Popular Cardiology Topics - FDA approval of Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), and new pacemaker technologies.

The top two articles on DAIC from 2018 included the FDA approval of Andexxa, the first antidote indicated for patients treated with the anticoagulants rivaroxaban (Xarelto) and apixaban (Eliquis), and an article on new pacemaker technologies. 

Feature | January 04, 2019 | Dave Fornell, Editor
January 4, 2018 — Here is the top cardiology content on the Diagnostic and Interventional Cardiology (DAIC) website...
Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab
News | Cardio-oncology | January 03, 2019
January 3, 2019 — Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage,...
FDA Approves Portola Pharmaceuticals' Prior Approval Supplement for Andexxa Generation 2 Manufacturing Process
News | Antiplatelet and Anticoagulation Therapies | January 02, 2019
January 2, 2019 — The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals’ Prior Approval...